For many decades, eye drops have been the standard of care for cataract patients. While vitreoretinal surgeons have enjoyed innovations in drug delivery, cataract surgeons have accepted topical therapy despite many associated problems. Dexycu (dexamethasone intraocular suspension) was approved by the FDA in 2018 for the reduction of postop inflammation. This bioerodible dexamethasone spherule was blindly injected through the pupil and could cause tissue-related complications. This study evaluating the injection of Dexycu into a new location, the capsular bag, proved very promising. It was conducted independently and without support of the manufacturer.